Delcath Systems (DCTH)
(Delayed Data from NSDQ)
$9.00 USD
-0.08 (-0.88%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $9.01 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DCTH 9.00 -0.08(-0.88%)
Will DCTH be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DCTH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DCTH
Delcath Systems Stock Gains on Positive CHEMOSAT Melanoma Data
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue Estimates
DCTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy?
Here's What Could Help Delcath Systems (DCTH) Maintain Its Recent Price Strength
Beat the Market Like Zacks: Goldman Sachs, Micron, Amgen in Focus
Other News for DCTH
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems management to meet with BTIG
Delcath Systems management to meet with BTIG
Delcath Systems management to meet with Craig-Hallum
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT? in Metastatic Uveal Melanoma Subgroups